Aller au contenu principal

 Articles scientifiques

Cytokine Landscape in Central Nervous System Metastases.

Auteurs : Marin J, Journe F, Ghanem GE, Awada A, Kindt N
Année : 2022
Journal : Biomedicines
Volume : 10

Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.

Auteurs : Caparica R, Ma Y, de Angelis C, Richard F, Desmedt C, Awada A, Piccart M, Perez EA, Moreno-Aspitia A, Badve S, Thompson EA, de Azambuja E
Année : 2022
Journal : Clin Breast Cancer
Volume : 22
Pages : 308-318

First-in-man, first-in-class phase I study with the monopolar spindle 1 kinase inhibitor S81694 administered intravenously in adult patients with advanced, metastatic solid tumours.

Auteurs : Schöffski P, Awada A, de la Bigne AM, Felloussi Z, Burbridge M, Cantero F, Colombo R, Maruzzelli S, Ammattatelli K, de Jonge M, Aftimos P, Dumez H, Sleijfer S
Année : 2022
Journal : Eur J Cancer
Volume : 169
Pages : 135-145

Antitumor Activity of Lurbinectedin, a Selective Inhibitor of Oncogene Transcription, in Patients with Relapsed Ewing Sarcoma: Results of a Basket Phase II Study.

Auteurs : Subbiah V, Braña I, Longhi A, Boni V, Delord JP, Awada A, Boudou-Rouquette P, Sarantopoulos J, Shapiro GI, Elias A, Ratan R, Fernandez C, Kahatt C, Cullell-Young M, Siguero M, Zeaiter A, Chawla SP
Année : 2022
Journal : Clin Cancer Res
Volume : 28
Pages : 2762-2770

MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitie

Auteurs : Awada A, Gombos A
Année : 2022
Journal : TBCR
Volume : -
Pages : 4 pages

Understanding Molecular Mechanisms of Phenotype Switching and Crosstalk with TME to Reveal New Vulnerabilities of Melanoma.

Auteurs : Najem A, Soumoy L, Sabbah M, Krayem M, Awada A, Journe F, Ghanem GE
Année : 2022
Journal : Cells
Volume : 11

Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.

Auteurs : Capdevila J, Awada A, Führer-Sakel D, Leboulleux S, Pauwels P
Année : 2022
Journal : Cancer Treat Rev
Volume : 106
Pages : 102380

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Année : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pages : 38

Incidental finding of solitary fibrous tumor of male breast: case report and review of literature.

Auteurs : El-Helou E, Zaiter M, Hoang H, Lelie B, Larsimont D, Awada A, Grosu F, Veys I, Pop CF
Année : 2022
Journal : Rom J Morphol Embryol
Volume : 63
Pages : 653-657

Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).

Auteurs : Martinez Chanza N, Soukane L, Barthelemy P, Carnot A, Gil T, Casert V, Vanhaudenarde V, Sautois B, Staudacher L, Van Den Brande J, Culine S, Seront E, Gizzi M, Albisinni S, Tricard T, Fantoni JC, Paesmans M, Caparica R, Roumeguere T, Awada A
Année : 2021
Journal : BMC Cancer
Volume : 21
Pages : 1292

Tyrosine-Dependent Phenotype Switching Occurs Early in Many Primary Melanoma Cultures Limiting Their Translational Value.

Auteurs : Najem A, Wouters J, Krayem M, Rambow F, Sabbah M, Sales F, Awada A, Aerts S, Journe F, Marine JC, Ghanem GE
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 780654

Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research.

Auteurs : Cogels MM, Rouas R, Ghanem GE, Martinive P, Awada A, Van Gestel D, Krayem M
Année : 2021
Journal : Front Oncol
Volume : 11
Pages : 784947

Fluorescent Multiplex Immunohistochemistry Coupled With Other State-Of-The-Art Techniques to Systematically Characterize the Tumor Immune Microenvironment.

Auteurs : Boisson A, Noël G, Saiselet M, Rodrigues-Vitória J, Thomas N, Fontsa ML, Sofronii D, Naveaux C, Duvillier H, Craciun L, Larsimont D, Awada A, Detours V, Willard-Gallo K, Garaud S
Année : 2021
Journal : Front Mol Biosci
Volume : 8
Pages : 673042

Current landscape of ESMO/ASCO Global Curriculum adoption and medical oncology recognition: a global survey.

Auteurs : Cufer T, Kosty M, Osterlund P, Jezdic S, Pyle D, Awada A, Close J, El-Saghir N, Lordick F, Rutkowski P, Tfayli A, Wildiers H
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100219

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours.

Auteurs : van Bussel MTJ, Awada A, de Jonge MJA, Mau-Sørensen M, Nielsen D, Schöffski P, Verheul HMW, Sarholz B, Berghoff K, El Bawab S, Kuipers M, Damstrup L, Diaz-Padilla I, Schellens JHM
Année : 2021
Journal : Br J Cancer
Volume : 124
Pages : 728-735

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial.

Auteurs : Lebbé C, Italiano A, Houédé N, Awada A, Aftimos P, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Raymond E, Faivre S, Pages C, Gomez-Roca C, Schueler A, Goodstal S, Massimini G, Delord JP
Année : 2021
Journal : Target Oncol
Volume : 16
Pages : 47-57

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors.

Auteurs : Delord JP, Italiano A, Awada A, Aftimos P, Houédé N, Lebbé C, Pages C, Lesimple T, Dinulescu M, Schellens JHM, Leijen S, Rottey S, Kruse V, Kefford R, Faivre S, Gomez-Roca C, Scheuler A, Massimini G, Raymond E
Année : 2021
Journal : Target Oncol
Volume : 16
Pages : 37-46

FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Année : 2021
Journal : NPJ Breast Cancer
Volume : 7
Pages : 125

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer.

Auteurs : Schettini F, Giuliano M, Lambertini M, Bartsch R, Pinato DJ, Onesti CE, Harbeck N, Lüftner D, Rottey S, van Dam PA, Zaman K, Mustacchi G, Gligorov J, Awada A, Campone M, Wildiers H, Gennari A, Tjan-Heijnen VCG, Cortes J, Locci M, Paris I, Del Mastro L, De Placido S, Martín M, Jerusalem G, Venturini S, Curigliano G, Generali D
Année : 2021
Journal : Cancers (Basel)
Volume : 13

Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology.

Auteurs : Castelo-Branco L, Awada A, Pentheroudakis G, Perez-Gracia JL, Mateo J, Curigliano G, Banerjee S, Giuliani R, Lordick F, Cervantes A, Tabernero J, Peters S
Année : 2021
Journal : ESMO Open
Volume : 6
Pages : 100237